Biomarkers in Ulcerative Colitis

Publication Date: February 21, 2023

Key Points

Key Points

  • There is an important need for understanding how noninvasive biomarkers may serve as accurate and reliable surrogates for endoscopic assessment of inflammation.
  • Commonly available biomarkers are well-established as surrogate tests for endoscopic assessment of disease and in longitudinal monitoring of patients with an established diagnosis of ulcerative colitis (UC).
  • This guideline focuses on the following biomarkers: serum C-reactive protein (CRP), fecal calprotectin, and fecal lactoferrin.

Diagnosis

...agnosis...

...of Recommendations...

...With Ulcerative Colitis in Symptomatic Remiss...

...ith UC in symptomatic remission, the AGA sug...

...calprotectin...

...cal lactoferrin (C, L)620...

...(C, VL)Implementation consideration: Normal C...

...ts with UC in symptomatic remission but elevated s...

...tients With Symptomatically Active Ulce...

...atients with symptomatically active UC,...

...alprotectin >150 μg/g (C, L)620...

...d fecal lactoferrin (C, VL)6...

...evated CRP (C, M)620

...n patients with UC with mild symptoms, w...

...UC with mild symptoms, with normal...

...reat-to-target Strategies for Ulce...

...ents with UC, the AGA makes no recom...


...of Key Considerations When Using Biomarkers f...


Treatment

...atment...

...uences of Diagnostic Test Results on Pati...